Aug 2026
Design, Synthesis, and Antitumor Activity Evaluation of Novel Dual A2A/A2B Adenosine Receptor Antagonists.
The development of compound 45 is reported, a novel imidazopyrazine derivative acting as a long-lasting, dual A2A/A2B receptor antagonist with nanomolar in vitro potency, providing high oral bioavailability and systemic exposure across multiple preclinical species.
M. Gałęzowski, M. Kujawa, A. Bobowska et al.
· Journal of Medicinal Chemist... · 0 citations